Tacedinaline

Tacedinaline is an anti-cancer drug which inhibits histone deacetylases. In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of Tacedinaline induced complete remissions. Tacedinaline/ara-C was very active against BNML (Brown Norway rat acute myelocytic leukemia). The combinations of CI-994/daunorubicin and CI-994/mitoxantrone were also active against BNML.

Synonyms: CI-994; PD-123654; GOE-5549; Acetyldinaline; 4-Acetamido-N-(2-aminophenyl)benzamide
Technical Data: Molecular Weight - 269.31; Molecular formula - C15H15N3O2; CAS No - 112522-64-2

Ordering Information: Product Number - EC-000.2116
Price and Availability: Inquire
This product is also available to buy in bulk quantities.

Special offer
We are pleased to offer you set of eight HDAC inhibitors* at the best current market price:
$600/8 inhibitors* x 10 mg
$1100/8 inhibitors* x 50 mg
$1450/8 inhibitors* x 100 mg
Shipping and handling costs: $150
Delivery time: 5-10 days by courier from stock.
This special sale is for limited time only
* - Suberoylanilide Hydroxamic Acid (SAHA); Entinostat (MS-275); Tacedinaline (CI-994); BML-210; M344; Mocetinostat (MGCD0103); PXD101; LBH-589.

References:
1. Hubeek I, et al. CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep. 2008 Jun;19(6):1517-23.
2. Loprevite M, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48.
3. Kouraklis G, et al. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep. 2006 Feb;15(2):489-94.

Related service: collection of Histone Deacetylase Inhibitors.